Signal transduction inhibition: Results from phase I clinical trials in chronic myeloid leukemia

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The tyrosine kinase inhibitor, imatinib mesylate (Gleevec™, Novartis Pharmaceuticals Corp, East Hanover, NJ) (formerly STI571) showed significant antileukemic activity with minimal toxicity in preclinical studies. Based on these data, a phase I clinical trial was conducted in patients with chronic myeloid leukemia (CML) who failed other treatment options. Once therapeutic doses were attained, 53 of 54 patients (98%) in the chronic phase achieved hematologic remissions. With prolonged therapy of 2 to 5 months duration, a growing percentage of patients achieved cytogenetic responses. Imatinib mesylate also has activity as a single agent in CML blast crisis and in patients with Ph+ acute lymphocytic leukemia (ALL). Although responses tend not to be durable, 20% of patients with myeloid blast crisis are in continuous remission for periods up to 1 year. Ongoing clinical studies are directed at optimizing the use of imatinib mesylate.

Original languageEnglish (US)
Pages (from-to)9-14
Number of pages6
JournalSeminars in Hematology
Volume38
Issue number3 SUPPL. 8
StatePublished - 2001

Fingerprint

Clinical Trials, Phase I
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Signal Transduction
Blast Crisis
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cytogenetics
Protein-Tyrosine Kinases
Therapeutics
Imatinib Mesylate
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology

Cite this

Signal transduction inhibition : Results from phase I clinical trials in chronic myeloid leukemia. / Druker, Brian.

In: Seminars in Hematology, Vol. 38, No. 3 SUPPL. 8, 2001, p. 9-14.

Research output: Contribution to journalArticle

@article{e63e5dada888499183bc70408dfcdc71,
title = "Signal transduction inhibition: Results from phase I clinical trials in chronic myeloid leukemia",
abstract = "The tyrosine kinase inhibitor, imatinib mesylate (Gleevec™, Novartis Pharmaceuticals Corp, East Hanover, NJ) (formerly STI571) showed significant antileukemic activity with minimal toxicity in preclinical studies. Based on these data, a phase I clinical trial was conducted in patients with chronic myeloid leukemia (CML) who failed other treatment options. Once therapeutic doses were attained, 53 of 54 patients (98{\%}) in the chronic phase achieved hematologic remissions. With prolonged therapy of 2 to 5 months duration, a growing percentage of patients achieved cytogenetic responses. Imatinib mesylate also has activity as a single agent in CML blast crisis and in patients with Ph+ acute lymphocytic leukemia (ALL). Although responses tend not to be durable, 20{\%} of patients with myeloid blast crisis are in continuous remission for periods up to 1 year. Ongoing clinical studies are directed at optimizing the use of imatinib mesylate.",
author = "Brian Druker",
year = "2001",
language = "English (US)",
volume = "38",
pages = "9--14",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 8",

}

TY - JOUR

T1 - Signal transduction inhibition

T2 - Results from phase I clinical trials in chronic myeloid leukemia

AU - Druker, Brian

PY - 2001

Y1 - 2001

N2 - The tyrosine kinase inhibitor, imatinib mesylate (Gleevec™, Novartis Pharmaceuticals Corp, East Hanover, NJ) (formerly STI571) showed significant antileukemic activity with minimal toxicity in preclinical studies. Based on these data, a phase I clinical trial was conducted in patients with chronic myeloid leukemia (CML) who failed other treatment options. Once therapeutic doses were attained, 53 of 54 patients (98%) in the chronic phase achieved hematologic remissions. With prolonged therapy of 2 to 5 months duration, a growing percentage of patients achieved cytogenetic responses. Imatinib mesylate also has activity as a single agent in CML blast crisis and in patients with Ph+ acute lymphocytic leukemia (ALL). Although responses tend not to be durable, 20% of patients with myeloid blast crisis are in continuous remission for periods up to 1 year. Ongoing clinical studies are directed at optimizing the use of imatinib mesylate.

AB - The tyrosine kinase inhibitor, imatinib mesylate (Gleevec™, Novartis Pharmaceuticals Corp, East Hanover, NJ) (formerly STI571) showed significant antileukemic activity with minimal toxicity in preclinical studies. Based on these data, a phase I clinical trial was conducted in patients with chronic myeloid leukemia (CML) who failed other treatment options. Once therapeutic doses were attained, 53 of 54 patients (98%) in the chronic phase achieved hematologic remissions. With prolonged therapy of 2 to 5 months duration, a growing percentage of patients achieved cytogenetic responses. Imatinib mesylate also has activity as a single agent in CML blast crisis and in patients with Ph+ acute lymphocytic leukemia (ALL). Although responses tend not to be durable, 20% of patients with myeloid blast crisis are in continuous remission for periods up to 1 year. Ongoing clinical studies are directed at optimizing the use of imatinib mesylate.

UR - http://www.scopus.com/inward/record.url?scp=0034868659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034868659&partnerID=8YFLogxK

M3 - Article

C2 - 11526596

AN - SCOPUS:0034868659

VL - 38

SP - 9

EP - 14

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 3 SUPPL. 8

ER -